JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) and raises the price target from $30 to $31.
August 12, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Tessa Romero maintains an Overweight rating on Edgewise Therapeutics and raises the price target from $30 to $31.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence in Edgewise Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100